Concordia wraps up $1.2 bln purchase of Covis Pharma from Cerberus

Concordia Healthcare Corp (TSX: CXR) has closed its previously announced acquisition of assets held by Switzerland's Covis Pharma Holdings SARL for US$1.2 billion in cash. The sellers in the transaction included U.S. private equity firm Cerberus Capital Management. The Oakville, Ontario-based Concordia, a healthcare company focused on legacy pharmaceutical products and orphan drugs, said the deal will advance its organic and acquisition-based growth strategy.

DealsCanadaNorth AmericaBriefs